Abstract
Mortality among patients with chronic kidney disease (CKD) is largely a consequence of cardiovascular disease (CVD) and is a particular concern given the increasing prevalence of CKD. Sterile inflammation triggered by activation of the innate immune system is an important driver of both CKD and associated CVD. Several endogenous mediators, including lipoproteins, crystals such as silica, urate and cholesterol crystals, or compounds released from dying cells interact with pattern recognition receptors expressed on a variety of different cell types, leading to the release of pro-inflammatory cytokines. Disturbed regulation of the haematopoietic system by damage-associated molecular patterns, or as a consequence of clonal haematopoiesis or trained innate immunity, also contributes to the development of inflammation. In observational and genetic association studies, inflammation is linked to the progression of CKD and cardiovascular events. In 2017, the CANTOS trial of canakinumab provided evidence that inhibiting inflammation driven by NLRP3–IL-1–IL-6-mediated signalling significantly reduced cardiovascular event rates in individuals with and without CKD. Other approaches to target innate immune pathways are now under investigation for their ability to reduce cardiovascular events and slow disease progression among patients with atherosclerosis and stage 3 and 4 CKD. This Review summarizes current understanding of the role of inflammation in the pathogenesis of CKD and its associated CVD, and how this knowledge may translate into novel therapeutics.
Key points
-
Sterile inflammation has an important role in the pathogenesis of chronic kidney disease (CKD) and cardiovascular disease (CVD).
-
Activation of the NLRP3 inflammasome by endogenous ligands represents an important driver of inflammation in both CKD and CVD.
-
CKD and CVD are associated with alterations in the haematopoietic system caused by changes in the haematopoietic niche, clonal haematopoiesis and trained innate immunity.
-
Epidemiological and genetic studies link inflammation with CKD progression and cardiovascular events.
-
Anti-inflammatory treatments that target the NLRP3 to IL-1 to IL-6 pathway of innate immunity, such as canakinumab and colchicine, reduce cardiovascular events, although use of colchicine may be limited for those with severe CKD.
-
Targeting inflammation represents an important therapeutic advance in CKD and CVD.
Similar content being viewed by others
References
USRDS. USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States (National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2020).
Chronic Kidney Disease Prognosis Consortium et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073–2081 (2010).
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296–1305 (2004).
Speer, T., Ridker, P. M., von Eckardstein, A., Schunk, S. J. & Fliser, D. Lipoproteins in chronic kidney disease: from bench to bedside. Eur. Heart J. 42, 2170–2185 (2021).
Liuzzo, G. et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engl. J. Med. 331, 417–424 (1994).
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P. & Hennekens, C. H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973–979 (1997).
Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836–843 (2000).
Amdur, R. L. et al. Inflammation and progression of CKD: the CRIC Study. Clin. J. Am. Soc. Nephrol. 11, 1546–1556 (2016).
Ridker, P. M. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur. Heart J. 37, 1720–1722 (2016).
Emerging Risk Factors, C. et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375, 132–140 (2010).
Ridker, P. M. et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20–28 (2005).
Bohula, E. A. et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 132, 1224–1233 (2015).
Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2008).
Oberg, B. P. et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 65, 1009–1016 (2004).
Keller, C. R. et al. Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int. 71, 239–244 (2007).
Shankar, A. et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int. 80, 1231–1238 (2011).
Batra, G. et al. Interleukin 6 and cardiovascular outcomes in patients with chronic kidney disease and chronic coronary syndrome. JAMA Cardiol. 6, 1440–1445 (2021).
Munoz Mendoza, J. et al. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int. 91, 711–719 (2017).
Sun, J. et al. Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clin. J. Am. Soc. Nephrol. 11, 1163–1172 (2016).
Shlipak, M. G. et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293, 1737–1745 (2005).
Schunk, S. J. et al. Interleukin-1α is a central regulator of leukocyte-endothelial adhesion in myocardial infarction and in chronic kidney disease. Circulation 144, 893–908 (2021).
Ridker, P. M., Tuttle, K. R., Perkovic, V., Libby, P. & MacFadyen, J. G. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehac444 (2022).
Zewinger, S., Schumann, T., Fliser, D. & Speer, T. Innate immunity in CKD-associated vascular diseases. Nephrol. Dial. Transpl. 31, 1813–1821 (2016).
Stenvinkel, P. et al. Chronic inflammation in chronic kidney disease progression: role of Nrf2. Kidney Int. Rep. 6, 1775–1787 (2021).
Kim, H. J. & Vaziri, N. D. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am. J. Physiol. Renal Physiol. 298, F662–F671 (2010).
Kobayashi, E. H. et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat. Commun. 7, 11624 (2016).
Ahmed, S. M., Luo, L., Namani, A., Wang, X. J. & Tang, X. Nrf2 signaling pathway: pivotal roles in inflammation. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 585–597 (2017).
Bauernfeind, F. G. et al. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183, 787–791 (2009).
Mariathasan, S. et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228–232 (2006).
Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361 (2010).
Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).
Boucher, D. et al. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. J. Exp. Med. 215, 827–840 (2018).
Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660–665 (2015).
Liu, X. et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535, 153–158 (2016).
Evavold, C. L. et al. The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages. Immunity 48, 35–44 e36 (2018).
Monteleone, M. et al. Interleukin-1β maturation triggers its relocation to the plasma membrane for gasdermin-D-dependent and -independent secretion. Cell Rep. 24, 1425–1433 (2018).
Kayagaki, N. et al. Non-canonical inflammasome activation targets caspase-11. Nature 479, 117–121 (2011).
Kayagaki, N. et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 341, 1246–1249 (2013).
Shi, J. et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514, 187–192 (2014).
Dickens, L. S. et al. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol. Cell 47, 291–305 (2012).
Gurung, P. et al. FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes. J. Immunol. 192, 1835–1846 (2014).
Gaidt, M. M. et al. Human monocytes engage an alternative inflammasome pathway. Immunity 44, 833–846 (2016).
Zewinger, S. et al. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat. Immunol. 21, 30–41 (2020).
Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519–550 (2009).
Abbate, A. et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ. Res. 126, 1260–1280 (2020).
Lukens, J. R. et al. RIP1-driven autoinflammation targets IL-1α independently of inflammasomes and RIP3. Nature 498, 224–227 (2013).
Kim, B. et al. The interleukin-1α precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front. Immunol. 4, 391 (2013).
Di Paolo, N. C. & Shayakhmetov, D. M. Interleukin 1α and the inflammatory process. Nat. Immunol. 17, 906–913 (2016).
Afonina, I. S. et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol. Cell 44, 265–278 (2011).
Burzynski, L. C. et al. The coagulation and immune systems are directly linked through the activation of interleukin-1α by thrombin. Immunity 50, 1033–1042.e6 (2019).
Ridker, P. M. & Rane, M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ. Res. 128, 1728–1746 (2021).
Notta, F. et al. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 333, 218–221 (2011).
Jacobsen, S. E. W. & Nerlov, C. Haematopoiesis in the era of advanced single-cell technologies. Nat. Cell Biol. 21, 2–8 (2019).
Laurenti, E. & Gottgens, B. From haematopoietic stem cells to complex differentiation landscapes. Nature 553, 418–426 (2018).
Velten, L. et al. Human haematopoietic stem cell lineage commitment is a continuous process. Nat. Cell Biol. 19, 271–281 (2017).
Wei, Q. & Frenette, P. S. Niches for hematopoietic stem cells and their progeny. Immunity 48, 632–648 (2018).
IL6R Genetics Consortium Emerging Risk Factors Collaboration et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379, 1205–1213 (2012).
Schunk, S. J. et al. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Eur. Heart J. 42, 1742–1756 (2021).
Dehghan, A. et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 123, 731–738 (2011).
Cai, T. et al. Association of interleukin 6 receptor variant with cardiovascular disease effects of interleukin 6 receptor blocking therapy: a phenome-wide association study. JAMA Cardiol. 3, 849–857 (2018).
Wetmore, J. B. et al. Interleukin-1 gene cluster polymorphisms predict risk of ESRD. Kidney Int. 68, 278–284 (2005).
Rocha, S. et al. Interleukin 6 (rs1800795) and pentraxin 3 (rs2305619) polymorphisms-association with inflammation and all-cause mortality in end-stage-renal disease patients on dialysis. Sci. Rep. 11, 14768 (2021).
Yu, Z., Zekavat, S. M., Honigberg, M. C. & Natarajan, P. Genetic IL-6 signaling modifies incident coronary artery disease risk in chronic kidney disease. J. Am. Coll. Cardiol. 79, 415–416 (2022).
Speer, T. et al. Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur. Heart J. 35, 3021–3032 (2014).
Schunk, S. J. et al. Guanidinylated apolipoprotein C3 (ApoC3) associates with kidney and vascular injury. J. Am. Soc. Nephrol. 32, 3146–3160 (2021).
Zewinger, S. et al. HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J. Am. Soc. Nephrol. 25, 1073–1082 (2014).
Zewinger, S. et al. Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur. Heart J. 36, 3007–3016 (2015).
Speer, T. et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 38, 754–768 (2013).
Zewinger, S. et al. Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease. Eur. Heart J. 38, 1597–1607 (2017).
Jovanovich, A., Isakova, T. & Stubbs, J. Microbiome and cardiovascular disease in CKD. Clin. J. Am. Soc. Nephrol. 13, 1598–1604 (2018).
Ross, R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340, 115–126 (1999).
Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).
Koeth, R. A. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576–585 (2013).
Docherty, M. H., O’Sullivan, E. D., Bonventre, J. V. & Ferenbach, D. A. Cellular senescence in the kidney. J. Am. Soc. Nephrol. 30, 726–736 (2019).
Campisi, J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 75, 685–705 (2013).
Childs, B. G., Durik, M., Baker, D. J. & van Deursen, J. M. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat. Med. 21, 1424–1435 (2015).
Coppe, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853–2868 (2008).
Acosta, J. C. et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006–1018 (2008).
Schunk, S. J., Floege, J., Fliser, D. & Speer, T. WNT-beta-catenin signalling - a versatile player in kidney injury and repair. Nat. Rev. Nephrol. 17, 172–184 (2021).
van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014).
Kuilman, T. et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019–1031 (2008).
Freund, A., Orjalo, A. V., Desprez, P. Y. & Campisi, J. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol. Med. 16, 238–246 (2010).
Anders, H. J. Of inflammasomes and alarmins: IL-1β and IL-1α in kidney disease. J. Am. Soc. Nephrol. 27, 2564–2575 (2016).
Mulay, S. R. & Anders, H. J. Crystallopathies. N. Engl. J. Med. 374, 2465–2476 (2016).
Mulay, S. R. & Anders, H. J. Crystal nephropathies: mechanisms of crystal-induced kidney injury. Nat. Rev. Nephrol. 13, 226–240 (2017).
Komada, T. et al. ASC in renal collecting duct epithelial cells contributes to inflammation and injury after unilateral ureteral obstruction. Am. J. Pathol. 184, 1287–1298 (2014).
Vilaysane, A. et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J. Am. Soc. Nephrol. 21, 1732–1744 (2010).
Wang, W. et al. Inflammasome-independent NLRP3 augments TGF-β signaling in kidney epithelium. J. Immunol. 190, 1239–1249 (2013).
Gong, W. et al. NLRP3 deletion protects against renal fibrosis and attenuates mitochondrial abnormality in mouse with 5/6 nephrectomy. Am. J. Physiol. Renal Physiol. 310, F1081–F1088 (2016).
Komada, T. et al. Macrophage uptake of necrotic cell DNA activates the AIM2 inflammasome to regulate a proinflammatory phenotype in CKD. J. Am. Soc. Nephrol. 29, 1165–1181 (2018).
Wu, Y. et al. AIM2 inflammasome contributes to aldosterone-induced renal injury via endoplasmic reticulum stress. Clin. Sci. 136, 103–120 (2022).
Lemos, D. R. et al. Interleukin-1beta activates a MYC-dependent metabolic switch in kidney stromal cells necessary for progressive tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 29, 1690–1705 (2018).
Leaf, I. A. et al. Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury. J. Clin. Invest. 127, 321–334 (2017).
Pindjakova, J. et al. Interleukin-1 accounts for intrarenal Th17 cell activation during ureteral obstruction. Kidney Int. 81, 379–390 (2012).
Kopp, J. B. et al. Podocytopathies. Nat. Rev. Dis. Prim. 6, 68 (2020).
Daneshpajouhnejad, P., Kopp, J. B., Winkler, C. A. & Rosenberg, A. Z. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nat. Rev. Nephrol. 18, 307–320 (2022).
Wu, J. et al. The key role of NLRP3 and STING in APOL1-associated podocytopathy. J. Clin. Invest. 131, e136329 (2021).
Abais, J. M. et al. NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia. Antioxid. Redox Signal. 18, 1537–1548 (2013).
Abais, J. M. et al. Nod-like receptor protein 3 (NLRP3) inflammasome activation and podocyte injury via thioredoxin-interacting protein (TXNIP) during hyperhomocysteinemia. J. Biol. Chem. 289, 27159–27168 (2014).
Shah, A. et al. Thioredoxin-interacting protein deficiency protects against diabetic nephropathy. J. Am. Soc. Nephrol. 26, 2963–2977 (2015).
Shahzad, K. et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int. 87, 74–84 (2015).
Shahzad, K. et al. Caspase-1, but not caspase-3, promotes diabetic nephropathy. J. Am. Soc. Nephrol. 27, 2270–2275 (2016).
Shahzad, K. et al. Stabilization of endogenous Nrf2 by minocycline protects against Nlrp3-inflammasome induced diabetic nephropathy. Sci. Rep. 6, 34228 (2016).
Zhuang, Y. et al. Albumin impairs renal tubular tight junctions via targeting the NLRP3 inflammasome. Am. J. Physiol. Renal Physiol. 308, F1012–F1019 (2015).
Zhuang, Y. et al. Mitochondrial dysfunction confers albumin-induced NLRP3 inflammasome activation and renal tubular injury. Am. J. Physiol. Renal Physiol. 308, F857–F866 (2015).
Liu, D. et al. Megalin/cubulin-lysosome-mediated albumin reabsorption is involved in the tubular cell activation of NLRP3 inflammasome and tubulointerstitial inflammation. J. Biol. Chem. 290, 18018–18028 (2015).
Warnatsch, A., Ioannou, M., Wang, Q. & Papayannopoulos, V. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 349, 316–320 (2015).
Westerterp, M. et al. Cholesterol efflux pathways suppress inflammasome activation, NETosis, and atherogenesis. Circulation 138, 898–912 (2018).
Freigang, S. et al. Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1α and sterile vascular inflammation in atherosclerosis. Nat. Immunol. 14, 1045–1053 (2013).
Stachon, P. et al. P2X7 deficiency blocks lesional inflammasome activity and ameliorates atherosclerosis in mice. Circulation 135, 2524–2533 (2017).
Kimura, Y. et al. Soluble uric acid promotes atherosclerosis via AMPK (AMP-activated protein kinase)-mediated inflammation. Arterioscler. Thromb. Vasc. Biol. 40, 570–582 (2020).
Karasawa, T. et al. Saturated fatty acids undergo intracellular crystallization and activate the NLRP3 inflammasome in macrophages. Arterioscler. Thromb. Vasc. Biol. 38, 744–756 (2018).
Orecchioni, M. et al. Olfactory receptor 2 in vascular macrophages drives atherosclerosis by NLRP3-dependent IL-1 production. Science 375, 214–221 (2022).
Paulin, N. et al. Double-strand DNA sensing Aim2 inflammasome regulates atherosclerotic plaque vulnerability. Circulation 138, 321–323 (2018).
Dutta, P. et al. Myocardial infarction activates CCR2+ hematopoietic stem and progenitor cells. Cell Stem Cell 16, 477–487 (2015).
van der Valk, F. M. et al. Increased haematopoietic activity in patients with atherosclerosis. Eur. Heart J. 38, 425–432 (2017).
Heidt, T. et al. Chronic variable stress activates hematopoietic stem cells. Nat. Med. 20, 754–758 (2014).
Barrett, T. J. et al. Chronic stress primes innate immune responses in mice and humans. Cell Rep. 36, 109595 (2021).
McAlpine, C. S. et al. Sleep modulates haematopoiesis and protects against atherosclerosis. Nature 566, 383–387 (2019).
Hoyer, F. F. et al. Bone marrow endothelial cells regulate myelopoiesis in diabetes mellitus. Circulation 142, 244–258 (2020).
Flynn, M. C. et al. Transient intermittent hyperglycemia accelerates atherosclerosis by promoting myelopoiesis. Circ. Res. 127, 877–892 (2020).
Nagareddy, P. R. et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 17, 695–708 (2013).
Sreejit, G. et al. Neutrophil-derived S100A8/A9 amplify granulopoiesis after myocardial infarction. Circulation 141, 1080–1094 (2020).
Sreejit, G. et al. Retention of the NLRP3 inflammasome-primed neutrophils in the bone marrow is essential for myocardial infarction-induced granulopoiesis. Circulation 145, 31–44 (2022).
Sager, H. B. et al. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction. Circulation 132, 1880–1890 (2015).
Hettwer, J. et al. Interleukin-1β suppression dampens inflammatory leukocyte production and uptake in atherosclerosis. Cardiovasc. Res. 1093/cvr/cvab337 (2021).
Frodermann, V. et al. Exercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cells. Nat. Med. 25, 1761–1771 (2019).
Song, W. M. & Colonna, M. Immune training unlocks innate potential. Cell 172, 3–5 (2018).
Christ, A. et al. Western diet triggers NLRP3-dependent innate immune reprogramming. Cell 172, 162–175.e14 (2018).
Mitroulis, I. et al. Modulation of myelopoiesis progenitors is an integral component of trained immunity. Cell 172, 147–161.e12 (2018).
Kaufmann, E. et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell 172, 176–190.e119 (2018).
Arts, R. J. W. et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23, 89–100.e105 (2018).
Edgar, L. et al. Hyperglycemia induces trained immunity in macrophages and their precursors and promotes atherosclerosis. Circulation 144, 961–982 (2021).
Temba, G. S. et al. Urban living in healthy Tanzanians is associated with an inflammatory status driven by dietary and metabolic changes. Nat. Immunol. 22, 287–300 (2021).
Koelwyn, G. J. et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nat. Med. 26, 1452–1458 (2020).
Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472–1478 (2014).
Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).
Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9–16 (2015).
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017).
Fuster, J. J. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355, 842–847 (2017).
Fidler, T. P. et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 592, 296–301 (2021).
Svensson, E. C. et al. TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiol. 7, 521–528 (2022).
Sano, S. et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. J. Am. Coll. Cardiol. 71, 875–886 (2018).
Sano, S. et al. JAK2 (V617F)-mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure. JACC Basic. Transl. Sci. 4, 684–697 (2019).
Pascual-Figal, D. A. et al. Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction. J. Am. Coll. Cardiol. 77, 1747–1759 (2021).
Abplanalp, W. T. et al. Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure. JAMA Cardiol. 5, 1170–1175 (2020).
Dorsheimer, L. et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 4, 25–33 (2019).
Assmus, B. et al. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. Eur. Heart J. 42, 257–265 (2021).
Mas-Peiro, S. et al. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. Eur. Heart J. 41, 933–939 (2020).
Abplanalp, W. T. et al. Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure. Circ. Res. 128, 216–228 (2021).
Vlasschaert, C. et al. Association of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease. J. Am. Soc. Nephrol. 33, 985–995 (2022).
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
Hung, A. M., Ellis, C. D., Shintani, A., Booker, C. & Ikizler, T. A. IL-1β receptor antagonist reduces inflammation in hemodialysis patients. J. Am. Soc. Nephrol. 22, 437–442 (2011).
Nowak, K. L. et al. IL-1 inhibition and vascular function in CKD. J. Am. Soc. Nephrol. 28, 971–980 (2017).
Nowak, K. L. et al. Interleukin-1 inhibition, chronic kidney disease-mineral and bone disorder, and physical function. Clin. Nephrol. 88, 132–143 (2017).
Hung, A. M. et al. IL-1 inhibition and function of the HDL-containing fraction of plasma in patients with stages 3 to 5 CKD. Clin. J. Am. Soc. Nephrol. 14, 702–711 (2019).
Ridker, P. M. et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391, 319–328 (2018).
Ridker, P. M. et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Eur. Heart J. 39, 3499–3507 (2018).
Ridker, P. M., MacFadyen, J. G., Thuren, T. & Libby, P. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Eur. Heart J. 41, 2153–2163 (2020).
Ridker, P. M. et al. Inhibition of interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J. Am. Coll. Cardiol. 71, 2405–2414 (2018).
Ridker, P. M. et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833–1842 (2017).
Solomon, D. H. et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial. Ann. Intern. Med. 169, 535–542 (2018).
Schieker, M. et al. Effects of interleukin-1β inhibition on incident hip and knee replacement: exploratory analyses from a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 173, 509–515 (2020).
Vallurupalli, M. et al. Effects of interleukin-1β inhibition on incident anemia: exploratory analyses from a randomized trial. Ann. Intern. Med. 172, 523–532 (2020).
Kleveland, O. et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur. Heart J. 37, 2406–2413 (2016).
Broch, K. et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 77, 1845–1855 (2021).
Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 2060–2069 (2021).
Muller, N. et al. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J. Lipid Res. 56, 1034–1042 (2015).
ZEUS - a research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammation. Clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT05021835 (2022).
Ganz, T. Anemia of inflammation. N. Engl. J. Med. 381, 1148–1157 (2019).
Pergola, P. E. et al. Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial. J. Am. Soc. Nephrol. 32, 211–222 (2021).
Deftereos, S. G. et al. Colchicine in cardiovascular disease: in-depth review. Circulation 145, 61–78 (2022).
Tardif, J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497–2505 (2019).
Nidorf, S. M. et al. Colchicine in patients with chronic coronary disease. N. Engl. J. Med. 383, 1838–1847 (2020).
Fiolet, A. T. L. et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur. Heart J. 42, 2765–2775 (2021).
Fernandez-Cuadros, M. E. et al. Colchicine-induced rhabdomyolysis: clinical, biochemical, and neurophysiological features and review of the literature. Clin. Med. Insights Arthritis Musculoskelet. Disord. 12, 1179544119849883 (2019).
Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380, 752–762 (2019).
Pergola, P. E. et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327–336 (2011).
de Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492–2503 (2013).
Rossing, P. et al. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. Kidney Int. 96, 1030–1036 (2019).
Rush, B. M. et al. Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice. Kidney Int. 99, 102–116 (2021).
Robledinos-Anton, N., Fernandez-Gines, R., Manda, G. & Cuadrado, A. Activators and inhibitors of NRF2: a review of their potential for clinical development. Oxid. Med. Cell Longev. 2019, 9372182 (2019).
Kirkland, J. L. & Tchkonia, T. Senolytic drugs: from discovery to translation. J. Intern. Med. 288, 518–536 (2020).
Baker, D. J. et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016).
Lee, D. H., Wolstein, J. M., Pudasaini, B. & Plotkin, M. INK4a deletion results in improved kidney regeneration and decreased capillary rarefaction after ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. 302, F183–F191 (2012).
Al-Douahji, M. et al. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int. 56, 1691–1699 (1999).
Wolf, G., Schanze, A., Stahl, R. A., Shankland, S. J. & Amann, K. p27Kip1 Knockout mice are protected from diabetic nephropathy: evidence for p27Kip1 haplotype insufficiency. Kidney Int. 68, 1583–1589 (2005).
Braun, H. et al. Cellular senescence limits regenerative capacity and allograft survival. J. Am. Soc. Nephrol. 23, 1467–1473 (2012).
Mylonas, K. J. et al. Cellular senescence inhibits renal regeneration after injury in mice, with senolytic treatment promoting repair. Sci. Transl. Med. 13, eabb0203 (2021).
Hickson, L. J. et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine 47, 446–456 (2019).
Goicoechea, M. et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J. Am. Soc. Nephrol. 17, S231–S235 (2006).
Davignon, J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109, III39–III43 (2004).
van der Aart-van der Beek, A. B., de Boer, R. A. & Heerspink, H. J. L. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat. Rev. Nephrol. 18, 294–306 (2022).
Kim, S. R. et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat. Commun. 11, 2127 (2020).
Heerspink, H. J. L. et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 62, 1154–1166 (2019).
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J. & Stompor, T. Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists. Int. J. Mol. Sci. 22, 10822 (2021).
Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).
Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740–756 (2018).
Kimber, C. et al. Randomized, placebo-controlled trial of rifaximin therapy for lowering gut-derived cardiovascular toxins and inflammation in CKD. Kidney360 1, 1206–1216 (2020).
Schulman, G. et al. Randomized placebo-controlled EPPIC trials of AST-120 in CKD. J. Am. Soc. Nephrol. 26, 1732–1746 (2015).
Mafra, D. et al. Food as medicine: targeting the uraemic phenotype in chronic kidney disease. Nat. Rev. Nephrol. 17, 153–171 (2021).
Meijers, B., Evenepoel, P. & Anders, H. J. Intestinal microbiome and fitness in kidney disease. Nat. Rev. Nephrol. 15, 531–545 (2019).
Nicklas, J. M. et al. Effect of dietary composition of weight loss diets on high-sensitivity C-reactive protein: the randomized POUNDS LOST trial. Obesity 21, 681–689 (2013).
Li, J. et al. Dietary inflammatory potential and risk of cardiovascular disease among men and women in the US. J. Am. Coll. Cardiol. 76, 2181–2193 (2020).
Estruch, R. et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N. Engl. J. Med. 378, e34 (2018).
Swanson, K. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477–489 (2019).
Mangan, M. S. J. et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat. Rev. Drug Discov. 17, 588–606 (2018).
Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 17, 78 (2017).
Soehnlein, O. & Libby, P. Targeting inflammation in atherosclerosis — from experimental insights to the clinic. Nat. Rev. Drug Discov. 20, 589–610 (2021).
Acknowledgements
T.S., S.J.S. and D.F. are supported by the Deutsche Forschungsgemeinschaft (DFG, SFB TRR 219, Project-ID 322900939).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.S. has received consulting and speaker fees from Amgen, Astellas, Bayer, GSK, Novartis, Novo Nordisk, Sanofi and Vifor. D.F. has received consulting and speaker fees from Amgen, Astellas, Bayer, Boehringer Ingelheim, GSK, Novartis, Novo Nordisk and Vifor. P.M.R. has received research grant support from Novartis, Kowa, Amarin and Pfizer, and has served as a consultant to Corvidia, Novartis, Flame, Agepha, AstraZeneca, Janssen, Civi Biopharm, SOCAR, Novo Nordisk, Upton, Omeicos, Health Outlook, Montai Health and Boehringer-Ingelheim. The other authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Nephrology thanks the anonymous reviewers for their contribution to the peer review of this work.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- Acute phase response
-
Non-specific reaction of the innate immune system to infections, inflammation and tissue injury.
- Residual inflammatory risk
-
Persisting risk of cardiovascular events due to inflammation despite high-intensity lipid-lowering therapy.
- Acute phase proteins
-
Cytokines, chemokines and other proteins released by leukocytes and other cell types during the acute phase response.
- Haematopoietic niche
-
A spatiotemporal compartmentalization of the bone marrow, in which resident cells, such as mesenchymal stroma cells, endothelial cells, cells of the endosteal niche and macrophages, interact with haematopoietic stem cells to orchestrate their differentiation and fate.
- Mendelian randomization analyses
-
Epidemiological methods to assess the association between single-nucleotide polymorphisms in distinct genes and outcomes to establish a causal effect between gene and phenotype.
- Phenome-wide association analyses
-
Epidemiological methods to assess the association between single-nucleotide polymorphisms and a large number of outcomes or phenotypes.
- Carbamylation
-
Post-translational modification of lysine residues within proteins induced by urea or myeloperoxidase-derived cyanate, leading to the formation of carbamylated lysine, which is also referred to as homocitrulline.
- Guanidinylation
-
Post-translational modification of lysine residues within proteins induced by guanidine or urea, leading to the formation of guanidinylated lysine, which is also referred to as homoarginine.
- Reverse cholesterol transport
-
Transport of cholesterol from peripheral tissues by high-density lipoprotein to the liver for biliary excretion.
- Epithelial-to-mesenchymal transition
-
Differentiation of epithelial cells to mesenchymal cells such as (myo)fibroblasts, which represents an important step in tissue fibrosis.
- Synbiotics
-
Dietary products or supplements containing probiotics (living microorganisms) and prebiotics (supplements modulating growth and/or metabolism of microorganisms).
- Prebiotics
-
Dietary products or supplements that modulate growth and/or metabolism of microorganisms, such as bacteria.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Speer, T., Dimmeler, S., Schunk, S.J. et al. Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. Nat Rev Nephrol 18, 762–778 (2022). https://doi.org/10.1038/s41581-022-00621-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-022-00621-9
- Springer Nature Limited